Screener
Arcus Biosciences RCUS Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $41M-74.4% | $17M-39.3% | $33M+26.9% | $26M-45.8% | $160M+310% | ||
| $113M-18.7% | $122M0.0% | $121M+19.8% | $141M+14.6% | $139M+20.9% | ||
| $24M-17.2% | $29M+3.6% | $26M-7.1% | $27M-10.0% | $29M-3.3% | ||
| $137M-18.5% | $151M+0.7% | $147M+14.0% | $168M+9.8% | $168M+15.9% | ||
| -$96M-1,100% | -$134M-9.8% | -$114M-10.7% | -$142M-35.2% | -$8M+92.5% | ||
| -234.1%-229pp | -788.2%-353pp | -345.5%+50.7pp | -546.2%-327pp | -5%+267pp | ||
| $3M+50.0% | $3M+200% | $2M0.0% | $3M+200% | $2M— | ||
| $5M-37.5% | $6M-40.0% | $8M-20.0% | $7M-46.2% | $8M-38.5% | ||
| -$91M— | -$128M-14.3% | -$106M-14.0% | -$135M-46.7% | $0+100% | ||
| $0— | $0— | $0-100% | $0— | $0— | ||
| -$91M— | -$128M-14.3% | -$106M-12.8% | -$135M-46.7% | $0+100% | ||
| -222%-222pp | -752.9%-353pp | -321.2%+40.3pp | -519.2%-328pp | 0%+238pp | ||
| -$0.72— | -$1.02+10.5% | -$0.90+12.6% | -$1.27-27.0% | $0.00+100% | ||
| -$93M-1,450% | -$132M-10.9% | -$111M-11.0% | -$140M-35.9% | -$6M+94.2% | ||
| -226.8%-223pp | -776.5%-351pp | -336.4%+48.3pp | -538.5%-324pp | -3.8%+263pp | ||
| -$96M-1,100% | -$134M-9.8% | -$114M-10.7% | -$142M-35.2% | -$8M+92.5% |
FAQ
- What is Arcus Biosciences's revenue?
- Arcus Biosciences (RCUS) generated $117.0M in revenue over the trailing twelve months, down 55.3% year over year.
- Is Arcus Biosciences profitable?
- Arcus Biosciences is not currently profitable: it reported a net loss of $460.0M over the trailing twelve months, a -393.2% net margin.
- What is Arcus Biosciences's earnings per share?
- Arcus Biosciences's diluted EPS over the trailing twelve months is $-3.91.
- Where does Arcus Biosciences's income statement data come from?
- Every line is extracted from Arcus Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
